Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.
Incyte Corp (INCY, $62.58) finds itself in the midst of a bearish trend, as indicated by A.I.dvisor's prediction of a potential Downtrend continuation. Shareholders have endured a challenging period, with a notable 38% decline in share price over the past three years and an additional 19% drop in the last quarter. To gain a comprehensive understanding of the company's current situation, it is essential to examine the correlation between shareholder returns and Incyte's underlying economics.
Over the past three years, while the broader market has returned approximately 40%, shareholders of Incyte have faced a contrasting experience with a significant decline of 38%. This divergence raises questions about the company's economic performance and its ability to generate returns for its shareholders.
Delving deeper into Incyte's economic performance, it becomes crucial to analyze whether the company's financials align with the disappointing shareholder returns. By scrutinizing key indicators, such as revenue growth, profitability, and efficiency, we can shed light on the underlying factors contributing to the company's stock performance.
Incyte Corp's economic performance has a critical role to play in determining its future prospects. By assessing the correlation between shareholder returns and the company's financial metrics, we can better understand whether there are any disparities or potential catalysts that may drive a turnaround. This analysis provides valuable insights for investors seeking to navigate the evolving landscape of Incyte Corp and make informed decisions regarding their investment strategy.
It is essential to approach Incyte Corp's current bearish trend with a comprehensive understanding of its underlying economics and the factors influencing its share price. By staying informed and aware of the correlation between shareholder returns and the company's financial performance, investors can make more informed decisions about their investment in Incyte and evaluate its future potential.
INCY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 09, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 28, 2024. You may want to consider a long position or call options on INCY as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
INCY moved above its 50-day moving average on October 28, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 197 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.246) is normal, around the industry mean (12.657). P/E Ratio (161.171) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.564) is also within normal values, averaging (1.971). INCY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.834) is also within normal values, averaging (225.870).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of drugs
Industry Biotechnology